Active ingredientGilteritinibCat. No. P-G032-001CAS 1254053-43-4Family · Pharmaceutical analytical standards
Gilteritinib
An oral FLT3 kinase inhibitor, approved in the United States in November 2018 for adults with relapsed or refractory acute myeloid leukaemia carrying a mutation of the FLT3 gene. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Alongside the drug, the FDA extended the use of a diagnostic test that detects the FLT3 mutation: the treatment is intended only for patients in whom the test finds it.
Go to the active ingredient →Active ingredientGilteritinibCat. No. P-G032-001CAS 1254053-43-4
Active ingredientGilteritinib HemifumarateCat. No. P-G032-002CAS 1254053-84-3
Isotopically labelledGilteritinib-d8Cat. No. P-G032-003CAS 2377109-74-3
ImpurityGilteritinib Impurity 1Cat. No. P-G032-004CAS 1254058-34-8
ImpurityGilteritinib Impurity 2Cat. No. P-G032-005
ImpurityGilteritinib Impurity 3Cat. No. P-G032-006CAS 2043019-99-2
ImpurityGilteritinib Impurity 4Cat. No. P-G032-007CAS 1373410-40-2
ImpurityGilteritinib N-Methyl N-Oxide ImpurityCat. No. P-G032-008
ImpurityGilteritinib N-Oxide ImpurityCat. No. P-G032-009No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.